Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Regulatory
500 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Belzutifan | US FDA | Clear Cell Renal Cell Carcinoma | as monotherapy, for treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). | approved | Aug 13, 2021 | openfda |
| Belzutifan | US FDA | Clear Cell Renal Cell Carcinoma | Renal Cell Carcinoma with a Clear Cell Component (ccRCC) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the adjuvant treatment of adult patients with ccRCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. | approved | Aug 13, 2021 | openfda |
| Bendamustine | US FDA | Indolent B-Cell Non-Hodgkin Lymphoma | Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. | approved | Jul 3, 2025 | openfda |
| Bendamustine | US FDA | Chronic Lymphocytic Leukemia | Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. | approved | Jul 3, 2025 | openfda |
| Bendamustine | US FDA | Indolent B-Cell Non-Hodgkin Lymphoma | Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. | approved | Dec 15, 2022 | openfda |
| Bendamustine | US FDA | Chronic Lymphocytic Leukemia | Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. | approved | Dec 15, 2022 | openfda |
| Bendamustine | US FDA | Indolent B-Cell Non-Hodgkin Lymphoma | Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1 ) | approved | Dec 7, 2022 | openfda |
| Bendamustine | US FDA | Chronic Lymphocytic Leukemia | Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. | approved | Dec 7, 2022 | openfda |
| Bendamustine | US FDA | Indolent B-Cell Non-Hodgkin Lymphoma | Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. | approved | Dec 7, 2022 | openfda |
| Bendamustine | US FDA | Indolent B-Cell Non-Hodgkin Lymphoma | Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. | approved | May 15, 2018 | openfda |
| Bendamustine | US FDA | Chronic Lymphocytic Leukemia | Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. | approved | May 15, 2018 | openfda |
| Bendamustine | US FDA | Indolent B-Cell Non-Hodgkin Lymphoma | Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. | approved | Dec 7, 2015 | openfda |
| Bendamustine | US FDA | Chronic Lymphocytic Leukemia | Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. | approved | Dec 7, 2015 | openfda |
| Bendamustine | US FDA | Chronic Lymphocytic Leukemia | Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. | approved | Mar 20, 2008 | openfda |
| Bendamustine | US FDA | Indolent B-Cell Non-Hodgkin Lymphoma | Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. | approved | Mar 20, 2008 | openfda |
| Bevacizumab | US FDA | Malignant Colorectal Neoplasm | Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Malignant Colon Neoplasm | Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Glioblastoma | Recurrent glioblastoma in adults. | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Renal Cell Carcinoma | Metastatic renal cell carcinoma in combination with interferon alfa. | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Hepatocellular Carcinoma | Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Malignant Cervical Neoplasm | Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Malignant Peritoneal Neoplasm | Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection | approved | Feb 26, 2004 | openfda |
| Bevacizumab | US FDA | Malignant Colorectal Neoplasm | Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. | approved | Feb 26, 2004 | openfda |
| Bexarotene | US FDA | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Targretin (bexarotene) gel 1% is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies. | approved | Jun 28, 2000 | openfda |
| Bexarotene | US FDA | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | TARGRETIN ® (bexarotene) Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. TARGRETIN (bexarotene) is a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. ( 1 ) | approved | Dec 29, 1999 | openfda |
| Bicalutamide | US FDA | Prostate Carcinoma | 1. INDICATIONS AND USAGE Bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2) ]. Bicalutamide tablets 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. (1) Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments. (1) | approved | Oct 4, 1995 | openfda |
| Binimetinib | US FDA | Melanoma | in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | approved | Jun 27, 2018 | openfda |
| Binimetinib | US FDA | Lung Non-Small Cell Carcinoma | in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. | approved | Jun 27, 2018 | openfda |
| Blinatumomab | US FDA | Acute Lymphoblastic Leukemia | CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. | approved | Dec 3, 2014 | openfda |
| Blinatumomab | US FDA | Acute Lymphoblastic Leukemia | CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. | approved | Dec 3, 2014 | openfda |
| Blinatumomab | US FDA | Acute Lymphoblastic Leukemia | Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). | approved | Dec 3, 2014 | openfda |
| Bortezomib | US FDA | Multiple Myeloma | treatment of adult patients with multiple myeloma | approved | Aug 26, 2024 | openfda |
| Bortezomib | US FDA | Mantle Cell Lymphoma | treatment of adult patients with mantle cell lymphoma | approved | Aug 26, 2024 | openfda |
| Bortezomib | US FDA | Mantle Cell Lymphoma | treatment of adult patients with mantle cell lymphoma | approved | Jul 27, 2022 | openfda |
| Bortezomib | US FDA | Multiple Myeloma | treatment of adult patients with multiple myeloma | approved | Jul 27, 2022 | openfda |
| Bortezomib | US FDA | Mantle Cell Lymphoma | Treatment of adult patients with mantle cell lymphoma. | approved | May 2, 2022 | openfda |
| Bortezomib | US FDA | Multiple Myeloma | Treatment of adult patients with multiple myeloma. | approved | May 2, 2022 | openfda |
| Bortezomib | US FDA | Mantle Cell Lymphoma | treatment of adult patients with mantle cell lymphoma | approved | May 13, 2003 | openfda |
| Bortezomib | US FDA | Multiple Myeloma | treatment of adult patients with multiple myeloma | approved | May 13, 2003 | openfda |
| Bosutinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) | approved | Sep 26, 2023 | openfda |
| Bosutinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) | approved | Sep 4, 2012 | openfda |
| Brentuximab Vedotin | US FDA | Classic Hodgkin Lymphoma | . • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation | approved | Aug 19, 2011 | openfda |
| Brentuximab Vedotin | US FDA | Classic Hodgkin Lymphoma | Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine | approved | Aug 19, 2011 | openfda |
| Brentuximab Vedotin | US FDA | Classic Hodgkin Lymphoma | . • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide | approved | Aug 19, 2011 | openfda |
| Brentuximab Vedotin | US FDA | Classic Hodgkin Lymphoma | . • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates | approved | Aug 19, 2011 | openfda |
| Brentuximab Vedotin | US FDA | Systemic Anaplastic Large Cell Lymphoma | . • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen | approved | Aug 19, 2011 | openfda |
| Busulfan | US FDA | Myeloid Leukemia | MYLERAN (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. | approved | Jun 26, 1954 | openfda |
| Cabazitaxel | US FDA | Castration-Resistant Prostate Carcinoma | JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ( 1 ) | approved | Jun 17, 2010 | openfda |
| Cabozantinib | US FDA | Renal Cell Carcinoma | patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab | approved | Apr 25, 2016 | openfda |
Data updated 16 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Cetuximab | 401 | 91 | 309 |
| Dasatinib | 306 | 173 | 133 |
| Erlotinib | 260 | 166 | 94 |
| Crizotinib | 255 | 135 | 120 |
| Vemurafenib | 238 | 129 | 109 |
| Gefitinib | 183 | 140 | 43 |
| Imatinib | 165 | 73 | 92 |
| Trametinib | 137 | 111 | 26 |
| Afatinib | 129 | 120 | 9 |
| Panitumumab | 127 | 34 | 93 |
| Trastuzumab | 127 | 90 | 37 |
| Olaparib | 105 | 102 | 3 |
| Dabrafenib | 99 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 66 |
| 33 |
| Sorafenib | 92 | 70 | 22 |
| Bosutinib | 91 | 32 | 59 |
| Imatinib Mesylate | 88 | 8 | 80 |
| Lapatinib | 84 | 63 | 21 |
| Palbociclib | 82 | 73 | 9 |
| Cisplatin | 76 | 45 | 30 |
| Sunitinib | 75 | 58 | 16 |
| Selumetinib | 72 | 58 | 14 |
| Nilotinib | 63 | 18 | 45 |
| Osimertinib | 62 | 48 | 14 |
| Chemotherapy | 61 | 39 | 22 |
| Axitinib | 57 | 17 | 40 |
| Larotrectinib | 57 | 50 | 7 |
| Dactolisib | 53 | 44 | 9 |
| Erdafitinib | 53 | 50 | 3 |
| Entrectinib | 50 | 43 | 7 |
| Pembrolizumab | 50 | 35 | 12 |
| Ponatinib | 45 | 39 | 6 |
| Irinotecan | 44 | 12 | 32 |
| Fluorouracil | 43 | 28 | 12 |
| Gemcitabine | 43 | 29 | 13 |
| Neratinib | 43 | 40 | 3 |
| Bevacizumab | 41 | 29 | 12 |
| Doxorubicin | 41 | 9 | 32 |
| Alectinib | 40 | 18 | 22 |
| Selpercatinib | 40 | 31 | 9 |
| Ceritinib | 38 | 25 | 13 |
| Venetoclax | 37 | 4 | 33 |
| Everolimus | 35 | 31 | 4 |
| Fulvestrant | 35 | 30 | 5 |
| Vismodegib | 35 | 9 | 26 |
| Carboplatin | 34 | 26 | 8 |
| Paclitaxel | 34 | 20 | 13 |
| Futibatinib | 32 | 29 | 3 |
| Midostaurin | 32 | 27 | 4 |
| Mercaptopurine | 31 | 2 | 28 |
| Rucaparib | 31 | 31 | 0 |
| Infigratinib | 30 | 26 | 4 |
| Docetaxel | 29 | 20 | 9 |
| Nivolumab | 29 | 20 | 6 |
| Thioguanine | 29 | 0 | 28 |
| Atezolizumab | 26 | 21 | 3 |
| Lorlatinib | 25 | 18 | 7 |
| Melphalan | 25 | 1 | 24 |
| Pazopanib | 25 | 24 | 1 |
| Pictilisib | 25 | 24 | 1 |
| Sirolimus | 25 | 20 | 5 |
| Pertuzumab | 24 | 24 | 0 |
| Trastuzumab Deruxtecan | 24 | 24 | 0 |
| Binimetinib | 23 | 22 | 1 |
| MDM2 Inhibitor AMGMDS3 | 23 | 1 | 22 |
| Regorafenib Anhydrous | 23 | 7 | 16 |
| Talazoparib | 23 | 23 | 0 |
| Tazemetostat | 23 | 23 | 0 |
| Capivasertib | 22 | 21 | 1 |
| Oxaliplatin | 22 | 6 | 16 |
| Quizartinib | 22 | 13 | 8 |
| Gilteritinib | 21 | 18 | 3 |
| Alpelisib | 20 | 15 | 5 |
| BRAF Inhibitor | 20 | 20 | 0 |
| Brigatinib | 20 | 11 | 9 |
| Enzalutamide | 20 | 8 | 12 |
| Temozolomide | 20 | 17 | 3 |
| Aspirin | 19 | 19 | 0 |
| Tamoxifen | 19 | 11 | 8 |
| Trastuzumab Emtansine | 19 | 10 | 9 |
| Cabozantinib | 18 | 17 | 1 |
| Capecitabine | 18 | 11 | 4 |
| Capmatinib | 18 | 15 | 1 |
| Sotorasib | 18 | 17 | 0 |
| Crenolanib | 17 | 16 | 1 |
| Cytarabine | 17 | 5 | 12 |
| Dacomitinib | 16 | 15 | 1 |
| Ivosidenib | 16 | 16 | 0 |
| Lestaurtinib | 16 | 15 | 1 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 16 | 14 | 2 |
| Pemetrexed | 16 | 11 | 5 |
| PI103 | 16 | 16 | 0 |
| Temsirolimus | 16 | 15 | 1 |
| ALK Inhibitor TAE684 | 15 | 12 | 3 |
| Daunorubicin | 15 | 4 | 11 |
| Immune Checkpoint Inhibitor | 15 | 12 | 2 |
| Tepotinib | 15 | 15 | 0 |
| Abiraterone | 14 | 3 | 11 |
| Encorafenib | 14 | 13 | 1 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 14 | 10 | 4 |
| Methotrexate | 14 | 2 | 9 |
| Platinum Compound | 14 | 13 | 1 |
| Pralsetinib | 14 | 8 | 6 |
| Tretinoin | 14 | 8 | 6 |
| Bafetinib | 13 | 1 | 12 |
| Dovitinib | 13 | 13 | 0 |
| Pexidartinib | 13 | 5 | 8 |
| Cobimetinib | 12 | 12 | 0 |
| Ibrutinib | 12 | 6 | 6 |
| Prednisone | 12 | 12 | 0 |
| Ruxolitinib | 12 | 12 | 0 |
| Belvarafenib | 11 | 8 | 3 |
| Durvalumab | 11 | 10 | 1 |
| Mirdametinib | 11 | 9 | 2 |
| Revumenib | 11 | 4 | 7 |
| Akt Inhibitor MK2206 | 10 | 9 | 1 |
| Asparaginase | 10 | 0 | 10 |
| Etoposide | 10 | 7 | 3 |
| PD173074 | 10 | 10 | 0 |
| R3Mab | 10 | 5 | 5 |
| JQ1 | 9 | 9 | 0 |
| PI3Ka/Di | 9 | 7 | 2 |
| PLX4720 | 9 | 5 | 4 |
| Vandetanib | 9 | 8 | 1 |
| Fexagratinib | 8 | 8 | 0 |
| Inavolisib | 8 | 8 | 0 |
| Ipilimumab | 8 | 6 | 1 |
| MEK Inhibitor CI-1040 | 8 | 8 | 0 |
| Niraparib | 8 | 8 | 0 |
| Ribociclib | 8 | 5 | 3 |
| Vorinostat | 8 | 7 | 1 |
| Azacitidine | 7 | 7 | 0 |
| Foretinib | 7 | 6 | 1 |
| GSK126 | 7 | 7 | 0 |
| Mitomycin | 7 | 6 | 1 |
| MTOR Inhibitor | 7 | 7 | 0 |
| Multikinase Inhibitor AEE788 | 7 | 5 | 2 |
| Panobinostat | 7 | 6 | 1 |
| PI-103 | 7 | 5 | 2 |
| Repotrectinib | 7 | 7 | 0 |
| Sonidegib | 7 | 4 | 3 |
| Sunvozertinib | 7 | 7 | 0 |
| Taselisib | 7 | 6 | 1 |
| VTP-50469 | 7 | 0 | 7 |
| Arsenic Trioxide | 6 | 3 | 3 |
| AZD3463 | 6 | 1 | 5 |
| Dabrafenib/Trametinib Regimen | 6 | 6 | 0 |
| Dinaciclib | 6 | 5 | 1 |
| Ipilimumab/Nivolumab Regimen | 6 | 6 | 0 |
| Linsitinib | 6 | 6 | 0 |
| Pacritinib | 6 | 6 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 6 | 6 | 0 |
| Tanespimycin | 6 | 6 | 0 |
| Trabectedin | 6 | 6 | 0 |
| Veliparib | 6 | 6 | 0 |
| Adavosertib | 5 | 5 | 0 |
| ALK Inhibitor ASP3026 | 5 | 1 | 4 |
| Amivantamab | 5 | 5 | 0 |
| Futuximab/Modotuximab Mixture | 5 | 5 | 0 |
| Hormone Therapy | 5 | 0 | 5 |
| MEK Inhibitor RO4987655 | 5 | 1 | 4 |
| Metformin | 5 | 5 | 0 |
| MTOR Kinase Inhibitor PP242 | 5 | 4 | 1 |
| PD1 Inhibitor | 5 | 4 | 1 |
| Pemigatinib | 5 | 4 | 1 |
| Radiation Therapy | 5 | 3 | 2 |
| Regorafenib | 5 | 4 | 1 |
| Rociletinib | 5 | 4 | 1 |
| Sapanisertib | 5 | 5 | 0 |
| SU11274 | 5 | 5 | 0 |
| Abemaciclib | 4 | 4 | 0 |
| Anti-PD1 Monoclonal Antibody | 4 | 3 | 1 |
| Anti-PD-L1 Monoclonal Antibody | 4 | 2 | 2 |
| Apitolisib | 4 | 4 | 0 |
| Arabinosylguanine | 4 | 1 | 3 |
| ARS-1620 | 4 | 3 | 0 |
| Asciminib | 4 | 4 | 0 |
| Bicalutamide | 4 | 1 | 3 |
| Buparlisib | 4 | 4 | 0 |
| Decitabine | 4 | 4 | 0 |
| Duligotuzumab | 4 | 4 | 0 |
| Enasidenib | 4 | 4 | 0 |
| Eprenetapopt | 4 | 4 | 0 |
| Exemestane | 4 | 4 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| JQEZ5 | 4 | 4 | 0 |
| Lenvatinib | 4 | 3 | 1 |
| Letrozole | 4 | 3 | 1 |
| Leucovorin | 4 | 4 | 0 |
| Linifanib | 4 | 4 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 4 | 2 | 2 |
| Nelarabine | 4 | 1 | 3 |
| Olutasidenib | 4 | 4 | 0 |
| Phosphatidylinositide 3-Kinase Inhibitor | 4 | 4 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 4 | 4 | 0 |
| PI3K/BET Inhibitor LY294002 | 4 | 4 | 0 |
| Poziotinib | 4 | 4 | 0 |
| Refametinib | 4 | 3 | 1 |
| Rogaratinib | 4 | 4 | 0 |
| Taxane Compound | 4 | 3 | 1 |
| Uprosertib | 4 | 4 | 0 |
| Vinorelbine | 4 | 4 | 0 |
| Vistusertib | 4 | 4 | 0 |
| Abiraterone Acetate | 3 | 0 | 3 |
| Adagrasib | 3 | 3 | 0 |
| AG1295 | 3 | 3 | 0 |
| Alisertib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| ATR Inhibitor | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| AZD-4547 | 3 | 3 | 0 |
| Birabresib | 3 | 3 | 0 |
| Bortezomib | 3 | 3 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 3 | 3 | 0 |
| Cabazitaxel | 3 | 2 | 1 |
| Canertinib | 3 | 3 | 0 |
| CDK Inhibitor SNS-032 | 3 | 3 | 0 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Deguelin | 3 | 3 | 0 |
| Dostarlimab | 3 | 3 | 0 |
| Dual IGF-1R/InsR Inhibitor BMS-754807 | 3 | 1 | 2 |
| EAP Protocol | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| FOLFOX-4 Regimen | 3 | 0 | 3 |
| IGF1R Monoclonal Antibody | 3 | 3 | 0 |
| Immunotherapy | 3 | 3 | 0 |
| Ipatasertib | 3 | 3 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 3 | 3 | 0 |
| KW2449 | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| Letetresgene Autoleucel | 3 | 3 | 0 |
| Lucitanib | 3 | 3 | 0 |
| Mobocertinib | 3 | 3 | 0 |
| PD98059 | 3 | 1 | 2 |
| Perifosine | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| R406 | 3 | 3 | 0 |
| Ramucirumab | 3 | 2 | 1 |
| RapaLink-1 | 3 | 1 | 2 |
| RDEA 119 | 3 | 3 | 0 |
| RG7112 | 3 | 2 | 1 |
| Ridaforolimus | 3 | 2 | 1 |
| Savolitinib | 3 | 2 | 1 |
| SU5614 | 3 | 0 | 3 |
| Tandutinib | 3 | 2 | 1 |
| Tegafur | 3 | 0 | 0 |
| Teprotumumab | 3 | 3 | 0 |
| Tremelimumab | 3 | 3 | 0 |
| Trichostatin A | 3 | 2 | 1 |
| Zongertinib | 3 | 3 | 0 |
| 5-Fluorouracil/Salicylic Acid Topical Solution | 2 | 0 | 2 |
| 7-Ethyl-10-Hydroxycamptothecin | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| AGS324 | 2 | 2 | 0 |
| ALK2 Inhibitor LDN-193189 | 2 | 2 | 0 |
| Alvocidib | 2 | 2 | 0 |
| Amrubicin | 2 | 1 | 1 |
| Angiogenesis Inhibitor | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| Anti-ErbB3 Monoclonal Antibody AV-203 | 2 | 2 | 0 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | 2 | 2 | 0 |
| Aromatase Inhibitor | 2 | 1 | 1 |
| Aumolertinib | 2 | 1 | 1 |
| Bazedoxifene | 2 | 1 | 1 |
| Belinostat | 2 | 0 | 0 |
| BET Inhibitor | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Carboplatin/Paclitaxel Regimen | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| CDK4/6 Inhibition | 2 | 1 | 1 |
| Cediranib | 2 | 2 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 2 | 2 | 0 |
| Chk1 Inhibitor | 2 | 2 | 0 |
| Copanlisib | 2 | 2 | 0 |
| Derazantinib | 2 | 2 | 0 |
| Dordaviprone | 2 | 2 | 0 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| EPZ011989 | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| FOLFIRI Regimen | 2 | 2 | 0 |
| Ganetespib | 2 | 1 | 1 |
| Ganitumab | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| Izorlisib | 2 | 2 | 0 |
| JQ-1 | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| L19IL2 | 2 | 2 | 0 |
| Levoleucovorin | 2 | 1 | 1 |
| Lometrexol | 2 | 2 | 0 |
| Lomustine | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Masitinib | 2 | 1 | 1 |
| Mocetinostat | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Nab-paclitaxel | 2 | 1 | 1 |
| Navtemadlin | 2 | 2 | 0 |
| Nimotuzumab | 2 | 2 | 0 |
| NSC348884 | 2 | 2 | 0 |
| NSC84167 | 2 | 2 | 0 |
| Omacetaxine Mepesuccinate | 2 | 2 | 0 |
| Palbociclib Regimen | 2 | 2 | 0 |
| Pan-AKT Kinase Inhibitor GSK690693 | 2 | 1 | 1 |
| PD-1 Ligand Inhibitor | 2 | 1 | 1 |
| Pidnarulex | 2 | 2 | 0 |
| Prexasertib | 2 | 2 | 0 |
| Quarfloxin | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| Rebemadlin | 2 | 1 | 1 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Rezatapopt | 2 | 2 | 0 |
| RG7356 | 2 | 1 | 1 |
| Rigosertib | 2 | 0 | 2 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| SAIT301 | 2 | 2 | 0 |
| Salinomycin | 2 | 2 | 0 |
| Salirasib | 2 | 2 | 0 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 2 | 2 | 0 |
| Setidegrasib | 2 | 2 | 0 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sotrastaurin Acetate | 2 | 2 | 0 |
| Spliceostatin A | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tarextumab | 2 | 2 | 0 |
| Therapeutic Tumor Infiltrating Lymphocytes | 2 | 1 | 1 |
| Tipifarnib | 2 | 2 | 0 |
| Trastuzumab Deruxtecan | 2 | 2 | 0 |
| Triciribine | 2 | 2 | 0 |
| Tucatinib | 2 | 2 | 0 |
| Tyrosine Kinase Inhibitor | 2 | 2 | 0 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| U0126 | 2 | 0 | 2 |
| Valproic Acid | 2 | 2 | 0 |
| Vatalanib | 2 | 2 | 0 |
| Verteporfin | 2 | 2 | 0 |
| Vincristine | 2 | 1 | 1 |
| Zenocutuzumab-zbco | 2 | 2 | 0 |
| Ziftomenib | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 3-Dimensional Conformal Radiation Therapy | 1 | 1 | 0 |
| 4'-(9-acridinylamino)methanesulfon-m-anisidide | 1 | 0 | 1 |
| 5-Fluoro-2-Deoxycytidine | 1 | 1 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| ACLY SiRNA | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| Afamitresgene Autoleucel | 1 | 1 | 0 |
| Afimoxifene | 1 | 0 | 1 |
| Agerafenib | 1 | 1 | 0 |
| AKTi-1/2 | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK/TRK Inhibitor TSR-011 | 1 | 0 | 1 |
| AMG511 | 1 | 1 | 0 |
| Aminoglutethimide | 1 | 1 | 0 |
| Amphotericin B | 1 | 1 | 0 |
| Amuvatinib | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| Anti-EGFR Monoclonal Antibody | 1 | 0 | 1 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Antisecretory Factor-enriched Egg Yolk Powder Supplement | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| Apalutamide | 1 | 0 | 1 |
| ARQ092 | 1 | 1 | 0 |
| ARS-853 | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | 1 | 1 | 0 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZ20 | 1 | 1 | 0 |
| AZ628 | 1 | 1 | 0 |
| AZ909 | 1 | 1 | 0 |
| Azathioprine | 1 | 0 | 0 |
| AZD5438 | 1 | 1 | 0 |
| Barasertib | 1 | 1 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Befotertinib | 1 | 1 | 0 |
| Berzosertib | 1 | 1 | 0 |
| Bevacizumab/Lomustine Regimen | 1 | 1 | 0 |
| Bimiralisib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bone Marrow Transplantation | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| CAN508 | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| Carfilzomib | 1 | 1 | 0 |
| Carmustine | 1 | 1 | 0 |
| C-DIM 12 | 1 | 0 | 1 |
| Celecoxib | 1 | 1 | 0 |
| Cetuximab/Encorafenib Regimen | 1 | 1 | 0 |
| Cetuximab/Irinotecan Regimen | 1 | 0 | 1 |
| CH6953755 | 1 | 1 | 0 |
| CH7233163 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| Chlorambucil | 1 | 1 | 0 |
| Chloroquine | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cixutumumab | 1 | 1 | 0 |
| C-Met Inhibitor | 1 | 1 | 0 |
| Conatumumab | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Cyclophosphamide | 1 | 1 | 0 |
| Cyproterone Acetate | 1 | 0 | 1 |
| Dacarbazine | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Daromun | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Disitamab Vedotin | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Donor Lymphocyte Infusion | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| DVP Regimen | 1 | 0 | 1 |
| EFTX-G12V | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Elacestrant | 1 | 1 | 0 |
| Elimusertib | 1 | 1 | 0 |
| Endocrine Drug Therapy | 1 | 1 | 0 |
| Enfortumab Vedotin | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Epirubicin | 1 | 1 | 0 |
| EPZ004777 | 1 | 1 | 0 |
| ERBB3 Inhibitor | 1 | 1 | 0 |
| Erdafitinib Regimen | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Everolimus/Exemestane Regimen | 1 | 1 | 0 |
| EZH2 Inhibitor | 1 | 1 | 0 |
| FAC Regimen | 1 | 0 | 1 |
| FACT Complex-targeting Curaxin CBL0137 | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| FEC Regimen | 1 | 0 | 1 |
| Fedratinib | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| FGFR Inhibitor ASP5878 | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| Fludarabine | 1 | 1 | 0 |
| Flutamide | 1 | 0 | 1 |
| FOLFIRI-Panitumumab Regimen | 1 | 0 | 1 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| FOLFOX Regimen | 1 | 1 | 0 |
| G007-LK | 1 | 1 | 0 |
| G-573 | 1 | 1 | 0 |
| Galeterone | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| GDC-0879 | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| GF109203X | 1 | 1 | 0 |
| GNE-617 | 1 | 1 | 0 |
| Go6983 | 1 | 1 | 0 |
| GPI-15427 | 1 | 1 | 0 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Guadecitabine | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HCI-2509 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HDAC Inhibitor REC-2282 | 1 | 1 | 0 |
| HDM2 Inhibitor MK-8242 | 1 | 1 | 0 |
| HER2 Inhibitor CP-724,714 | 1 | 0 | 1 |
| Hydroxychloroquine | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| Idelalisib | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Immunomodulatory Oligonucleotide | 1 | 1 | 0 |
| Inhibitor | 1 | 1 | 0 |
| Iniparib | 1 | 1 | 0 |
| Interventional Radiology Procedure | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| Ionizing Radiotherapy | 1 | 0 | 1 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| Ixazomib | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| JQ1 Compound | 1 | 1 | 0 |
| JW55 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| KG5 | 1 | 0 | 1 |
| KU-0060648 | 1 | 1 | 0 |
| Lasofoxifene | 1 | 1 | 0 |
| Lenalidomide | 1 | 0 | 1 |
| Leuprolide | 1 | 1 | 0 |
| Lonafarnib | 1 | 0 | 1 |
| Luminespib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Lysine | 1 | 0 | 1 |
| MAP855 | 1 | 1 | 0 |
| Margetuximab | 1 | 1 | 0 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| MEK-1/MEKK-1 Inhibitor E6201 | 1 | 1 | 0 |
| MEK Inhibitor GDC-0623 | 1 | 1 | 0 |
| MEK Inhibitor REC-4881 | 1 | 1 | 0 |
| Menin Inhibitor | 1 | 1 | 0 |
| MET Tyrosine Kinase Inhibitor SGX523 | 1 | 1 | 0 |
| Molibresib | 1 | 1 | 0 |
| Monomethyl Auristatin E | 1 | 0 | 1 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Multi-subtype Natural Human Leukocyte Interferon Alpha | 1 | 0 | 1 |
| MVT Regimen | 1 | 0 | 1 |
| Nano TACs | 1 | 1 | 0 |
| Naquotinib | 1 | 0 | 1 |
| NCT00137111 | 1 | 1 | 0 |
| Nedaplatin | 1 | 0 | 1 |
| Niacinamide | 1 | 0 | 1 |
| Nilutamide | 1 | 0 | 1 |
| Ningetinib | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| Nirogacestat | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| NOTCH1 Antibody (PF-06293622) | 1 | 1 | 0 |
| NU7441 | 1 | 1 | 0 |
| Nutlin-3 | 1 | 1 | 0 |
| NVP-AEW541 | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| O6-Benzylguanine | 1 | 1 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Omipalisib | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Panitumumab Regimen | 1 | 1 | 0 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 | 1 | 1 | 0 |
| Pan-RAF Inhibitor LY3009120 | 1 | 1 | 0 |
| PARP Inhibitor ABT-888 | 1 | 1 | 0 |
| PARP Inhibitor AZD2461 | 1 | 1 | 0 |
| Pasireotide | 1 | 1 | 0 |
| Patidegib | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| Patritumab Deruxtecan | 1 | 1 | 0 |
| PCV Regimen | 1 | 1 | 0 |
| PD-180970 | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Pegargiminase | 1 | 1 | 0 |
| Peginterferon Alfa-2a | 1 | 1 | 0 |
| Peginterferon Alfa-2b | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pemrametostat | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| Picoplatin | 1 | 0 | 1 |
| Pictilisib Bismesylate | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Pixantrone | 1 | 0 | 1 |
| Platinum Doublet | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| PSI | 1 | 1 | 0 |
| Pyridostatin | 1 | 1 | 0 |
| Pyrimidine Antagonist | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| Quisinostat | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| RG5 | 1 | 0 | 1 |
| Rilotumumab | 1 | 1 | 0 |
| Rindopepimut | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Samotolisib | 1 | 1 | 0 |
| SB202190 | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selinexor | 1 | 0 | 1 |
| Seribantumab | 1 | 1 | 0 |
| Sertraline | 1 | 1 | 0 |
| SGK1-Inh | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Tamibarotene | 1 | 0 | 1 |
| Tarloxotinib | 1 | 1 | 0 |
| Taxol | 1 | 0 | 1 |
| Telmisartan | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Tofacitinib | 1 | 1 | 0 |
| Topotecan | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| Tranilast | 1 | 1 | 0 |
| Trastuzumab Deruxtecan Regimen | 1 | 1 | 0 |
| Trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| TRK Inhibitor | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Tyrphostin AG 1478 | 1 | 1 | 0 |
| UNC1062 | 1 | 1 | 0 |
| UNC1999 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| VE-821 | 1 | 1 | 0 |
| VEGF/VEGFR Inhibitors | 1 | 1 | 0 |
| Vociprotafib | 1 | 0 | 0 |
| Volasertib | 1 | 1 | 0 |
| VTP50469 | 1 | 1 | 0 |
| VTX-11e | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WYE354 | 1 | 0 | 1 |
| WZ4002 | 1 | 0 | 1 |
| Zoledronic Acid | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.